Page 4 - Decision Diagnostic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CEO Charged in Rapid COVID-19 Test Scam Decision Diagnostics’ stock soared 1,500% in less than two months on allegedly false claims of a 15-second COVID-19 test. The US Securities and Exchange Commission (SEC) and the Department of Justice (DOJ) have charged the CEO of a California-based medical device company for allegedly leading a scheme to defraud investors out of millions of dollars by falsely claiming his company created a 15-second rapid COVID-19 test. Decision Diagnostics Inc. (DECN) CEO Keith Berman has been charged by the DOJ with one count of securities fraud and one count of mak...

Home / Top News / SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Decision Diagnostics Corp. (DECN) and Encourages DECN Investors to Contact the Firm SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Decision Diagnostics Corp. (DECN) and Encourages DECN Investors to Contact the Firm PHILADELPHIA, Dec. 19, 2020 (GLOBE NEWSWIRE) — Kaskela Law LLC announces that it is investigating Decision Diagnostics Corp. (“Decision Diagnostics”) (OTC: DECN) on behalf of the company’s stockholders. On December 17, 2020, the U.S. Securities and Exchange Commission (“SEC”) ...

DOJ and SEC Pursue Decision Diagnostics CEO on COVID-19 Testing Fraud Posted on 12/19/2020 The U.S. Justice Department revealed that a federal grand jury has indicted a California chief executive for allegedly concocting a scheme to defraud investors with false claims about a COVID-19 test. The false claim led to investor losses. Keith Berman, 67, the CEO of Decision Diagnostics Inc., was charged with one count of securities fraud and one count of making false statements, the DOJ said. The SEC temporarily suspended trading in Decision Diagnostics’ securities on April 23, 2020. The complaint...

SEC Charges Biotech Company and CEO with Fraud Concerning COVID-19 Blood Testing Device Washington, D.C.--(Newsfile Corp. - December 18, 2020) - The Securities and Exchange Commission today announced charges against California-based biotechnology company Decision Diagnostics Corp. and its CEO, Keith Berman, with making false and misleading claims in numerous press releases that the company had developed a working, break-through technology that could accurately detect Covid-19 through a quick blood test. The SEC temporarily suspended trading in Decision Diagnostics' securities on April 23, 20...

SEC Lawsuit Alleges Biotech Firm, CEO Misled Investors About COVID-19 Tests The U.S. Securities and Exchange Commission sued Decision Diagnostics Corp. and its chief executive for allegedly misleading investors by promising the biotechnology company could test for COVID-19 with a finger-prick of blood and provide accurate results in less than one minute. In a complaint filed on Thursday in Manhattan federal court, the SEC said Chief Executive Keith Berman made materially false statements between March and June about what he claimed was his company’s blood testing kit, and its efforts to obt...